Results 11 to 20 of about 461,371 (240)

Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer [PDF]

Cancer Medicine
Background Circulating tumor cells (CTCs) are pivotal liquid biopsy (LB) biomarkers for breast cancer (BC), offering non‐invasive insights into tumor progression and metastasis.
Saiying Ma, Xiaojia Wang, Peter Ping Lin, Lei Lei   +3 more
doaj   +2 more sources

Metastasis and circulating tumor cells [PDF]

EJIFCC, 2012
Cancer is a prominent cause of death worldwide. In most cases, it is not the primary tumor which causes death, but the metastases. Metastatic tumors are spread over the entire human body and are more difficult to remove or treat than the primary tumor ...
Dalum, G. van, Holland, L., Terstappen, L.W.M.M.   +2 more
core   +4 more sources

Circulating tumor cells [PDF]

Proceedings of the National Academy of Sciences, 2013
A typical cancerous tumor contains millions or even billions of cells harboring genetic mutations driving them to grow, divide, and invade the local tissue in which they’re embedded. However, as the cells proliferate, they don’t all stay in the neighborhood.
Plaks, Vicki, Koopman, Charlotte D, Werb, Zena   +2 more
openaire   +7 more sources

Circulating Tumor Cells for Glioma [PDF]

Frontiers in Oncology, 2021
Liquid biopsy has entered clinical applications for several cancers, including metastatic breast, prostate, and colorectal cancer for CTC enumeration and NSCLC for EGFR mutations in ctDNA, and has improved the individualized treatment of many cancers, but relatively little progress has been made in validating circulating biomarkers for brain ...
Yuan Fan'en, Baohui Liu, Qianxue Chen, Huikai Zhang, Yangzhi Qi   +4 more
openaire   +4 more sources

Tumor Hypoxia and Circulating Tumor Cells [PDF]

International Journal of Molecular Sciences, 2020
Circulating tumor cells (CTCs) are a rare tumor cell subpopulation induced and selected by the tumor microenvironment’s extreme conditions. Under hypoxia and starvation, these aggressive and invasive cells are able to invade the lymphatic and circulatory systems.
Tinganelli W., Durante M.
openaire   +5 more sources

Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer

Frontiers in Cell and Developmental Biology, 2021
Purpose: Monocarboxylate transporter 4 (MCT4) can influence the amount of lactate in the tumor microenvironment and further control cancer cell proliferation, migration, and angiogenesis.
Athina Markou, E. Tzanikou, G. Kallergi, E. Pantazaka, V. Georgoulias, A. Kotsakis, E. Lianidou   +6 more
doaj   +1 more source

Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer

Scientific Reports, 2023
Liquid biopsy (LB) provides a unique minimally invasive tool to follow-up cancer patients over time, to detect minimal residual disease (MRD), to study metastasis-biology and mechanisms of therapy-resistance.
Dimitra Stergiopoulou, Athina Markou, Areti Strati, Martha Zavridou, Eleni Tzanikou, Sophia Mastoraki, Galatea Kallergi, Vassilis Georgoulias, Evi Lianidou   +8 more
doaj   +1 more source

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)

Biomedicines, 2022
The PD-1/PD-L1 axis provides CTCs an escape route from the immune system. Phosphorylation of the ribosomal protein S6 is implicated in the same pathway, following mTOR activation. The aim of the study was to investigate the expression of PD-L1 and pS6 in
Evangelia Pantazaka, Aliki Ntzifa, Argyro Roumeliotou, Evi Lianidou, Vassilis Georgoulias, Athanasios Kotsakis, Galatea Kallergi   +6 more
doaj   +1 more source

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients

Scientific Reports, 2021
Liquid biopsy is a tool to unveil resistance mechanisms in NSCLC. We studied changes in gene expression in CTC-enriched fractions of EGFR-mutant NSCLC patients under osimertinib.
Aliki Ntzifa, Areti Strati, Galatea Kallergi, Athanasios Kotsakis, Vassilis Georgoulias, Evi Lianidou   +5 more
doaj   +1 more source

Circulating Tumor Cells [PDF]

JAMA Oncology, 2015
Circulating Tumor Cells (CTC) are shed from primary or secondary tumors. Prior studies have demonstrated that enumeration of CTC is a robust independent prognostic factor of progression free and overall survival in patients with early and metastatic breast cancer.
Daniel F. Hayes, Costanza Paoletti
openaire   +5 more sources